PUNE, India, April 24, 2017 /PRNewswire/ --
According to a new market research report "Perfusion Systems Market (Cardiopulmonary Perfusion, by Component (Heart-lung Machines, Oxygenators), Ex Vivo Organ Perfusion, Technique (Hypothermic, Normothermic), Cell Perfusion, by Type (Bioreactor, Microfluidic)) - Global Forecast to 2021", published by MarketsandMarkets™, the global market is expected to reach USD 1,198.8 Million by 2021 from USD 989.4 Million in 2016, at a CAGR of 3.9%.
Browse 74 market data Tables and 61 Figures spread through 152 Pages and in-depth TOC on "Perfusion Systems Market"
Early buyers will receive 10% customization on this report.
The growth of the market can be attributed to the increasing prevalence of cardiovascular & respiratory diseases, initiatives by governments & NGOs to encourage organ donation, increasing investment in cell-based research, and developments in biologics manufacturing. The high cost of organ transplantation and organ supply-demand gap, however, are expected to hinder the growth of the market.
The Perfusion Systems Market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region. By component, the cardiopulmonary Perfusion Systems Market is segmented into heart-lung machines, perfusion pumps, oxygenators, monitoring systems, cannulas, and other components. The oxygenators segment accounted for the largest share of the cardiopulmonary Perfusion Systems Market in 2016.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=164273069
Based on technique, the ex vivo organ Perfusion Systems Market is segmented into hypothermic machine perfusion and normothermic machine perfusion. The hypothermic machine perfusion segment held the largest share of the ex vivo organ Perfusion Systems Market in 2016 and is also projected to grow at the highest CAGR during the forecast period.
The global cell Perfusion Systems Market is segmented based on the type, as bioreactor perfusion systems, microfluidic perfusion systems, gravity or pressure-driven perfusion systems, and small-mammal organ perfusion systems.
The bioreactor perfusion systems segment held the largest share of the cell Perfusion Systems Market in 2016 and is projected to register the highest CAGR during the forecast period.
Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=164273069
Geographically, North America is estimated to account for the largest share of the global market, followed by Europe. The Asia-Pacific region is expected to witness the highest growth in the market during the forecast period. This growth will be particularly centered on China, Japan, and India.
The major players in the cardiopulmonary Perfusion Systems Market include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo organ perfusion system market are Lifeline Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading players in the cell Perfusion Systems Market.
Browse Related Reports:
Organ Preservation Market by Preservation Solution (UW/Custodiol HTK/Perfadex), Transportation Technique (Static Cold Storage/Hypothermic Machine Perfusion/Normothermic Machine Perfusion) & Organ Type (Kidneys/liver/lung) - Analysis & Forecasts to 2021.
Extracorporeal Membrane Oxygenation Machine Market by Modality (Veno-Arterial (VA), Veno-Venous (VV), Arterio-Venous (AV)), Application (Respiratory, Cardiac, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), and Region - Analysis & Forecasts to 2021.
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets